Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesilate in Patients With Inoperable or Recurrent Breast Cancer
Not Applicable
- Conditions
- Breast Cancer
- Registration Number
- JPRN-jRCT1080222004
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Inoperable breast cancer
Recurrent breast cancer
Exclusion Criteria
Corresponding to contraindication of eribulin mesilate
Not applicable to indications of eribulin mesilate
Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness diagnosed by imaging <br>Effectiveness diagnosed through various imagings such as CT, MRI, Echo or X-ray
- Secondary Outcome Measures
Name Time Method